1847 Holdings And 3 Other Stocks Under $1 Insiders Are Buying

The Dow Jones closed higher by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

HOOKIPA Pharma

• The Trade: HOOKIPA Pharma Inc. HOOK CEO Jorn Aldag acquired a total 10,000 shares an average price of $0.82. To acquire these shares, it cost around $8,192.
• What’s Happening: HOOKIPA Pharma recently reported preliminary Phase 2 data on HB-200 in combination with pembrolizumab in patients with HPV16+ head and neck cancers.
• What HOOKIPA Pharma Does: HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.

1847 Holdings

• The Trade: 1847 Holdings LLC EFSH 10% owner Strategic Risk LLC acquired a total of 443,413 shares at an average price of $0.23. The insider spent around $101,985.
• What’s Happening: 1847 projects revenue of $20 million for the second quarter, representing a 54% increase year over year.
• What 1847 Holdings Does: 1847 Holdings LLC is a diversified holding company. It operates in three segments: Retail and appliances, Construction, and Automotive Supplies.

Organicell Regenerative Medicine

• The Trade: Organicell Regenerative Medicine, Inc. OCEL 10% owner Skycrest Holdings LLC acquired a total of 320,710 shares at an average price of $0.01. To acquire these shares, it cost around $2,886.
• What’s Happening: Organicell Regenerative Medicine recently named Howard L. Golub, MD, PhD as its new Executive Vice President and Chief Science Officer.
• What Organicell Regenerative Medicine Does: Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine.

Check This Out: Investor Optimism Improves Ahead Of Inflation Data

Don’t forget to check out our premarket coverage here

Earth Science Tech

• The Trade: Earth Science Tech, Inc. ETST CEO Giorgio R Saumat acquired a total of 3,000 shares at an average price of $0.05. The insider spent $150 to buy those shares.
• What’s Happening: Earth Science Tech recently initiated the up-listing process to the OTCQB Exchange shortly after filing its March 31, 2023, YE report.
• What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.